| Project/Area Number |
26461615
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
細矢 光亮 福島県立医科大学, 医学部, 教授 (80192318)
橋本 浩一 福島県立医科大学, 医学部, 准教授 (50322342)
陶山 和秀 福島県立医科大学, 医学部, 講師 (90423798)
大原 信一郎 福島県立医科大学, 医学部, 助教 (00566846)
鈴木 順造 福島県立医科大学, 看護学部, 教授 (20171217)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | Acute renal injury / DAMPs / HUS / rhTM / HUSモデル / HMGB1 / VEGF / アンギオポエチン1 / 内皮細胞障害 / S100A8 / S100A9 |
|---|
| Outline of Final Research Achievements |
In order to clarify the efficacy of recombinant human soluble thrombomodulin(rhTM) for the treatment of typical hemolytic uremic syndrome(t-HUS), we examined changes in renal damage in t-HUS mice treated with rhTM or vehicle alone. We used severe and moderate t-HUS mice injected with shiga toxin(Stx) and lipopolysaccharide(LPS). The severe t-HUS mice were divided into two subgroups [an rhTM subgroup(Group A) and a saline subgroup(Group B)] along with the moderate t-HUS mice [an rhTM subgroup(Group C) and a saline subgroup(Group D)]. Groups E and F were healthy animals mice treated with rhTM or saline, respectively.
All mice in Group A remained alive. Serum creatinine level, and endothelial injury scores in the t-HUS mice treated with rhTM were lower than those in t-HUS mice treated with saline. Serum IL-6, TNF-α, and FDP levels at 24 hours after administration in Group A were lower than those in Group B. These results indicate that rhTM might afford an efficacious treatment for t-HUS.
|
